[Federal Register Volume 71, Number 231 (Friday, December 1, 2006)]
[Notices]
[Page 69593]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-20341]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on June 27, 2006, Noramco Inc., 
1440 Olympic Drive, Athens, Georgia 30601, made application by letter 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Oxymorphone (9652), a basic class of controlled 
substance listed in schedule II.
    The company plans to manufacture for in-house dosage form 
production and for sales to other dosage form manufacturers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Representative/ODL, 2401 
Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed 
no later than January 30, 2007.

    Dated: November 21, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E6-20341 Filed 11-30-06; 8:45 am]
BILLING CODE 4410-09-P